158 related articles for article (PubMed ID: 1754657)
1. Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia.
Goldman RS; Tandon R; Liberzon I; Goodson J; Greden JF
Psychopathology; 1991; 24(4):247-52. PubMed ID: 1754657
[TBL] [Abstract][Full Text] [Related]
2. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
Loas G; Noisette C; Legrand A; Delahousse J
Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
[TBL] [Abstract][Full Text] [Related]
3. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
4. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia.
Tandon R; Goldman RS; Goodson J; Greden JF
Biol Psychiatry; 1990 Jun; 27(12):1323-6. PubMed ID: 2364120
[No Abstract] [Full Text] [Related]
5. Validity of specific subscales of the positive and negative symptom scales in older schizophrenia outpatients.
McAdams LA; Harris MJ; Heaton SC; Bailey A; Fell R; Jeste DV
Schizophr Res; 1997 Oct; 27(2-3):219-26. PubMed ID: 9416651
[TBL] [Abstract][Full Text] [Related]
6. Positive and negative symptoms in neuroleptic-free psychotic inpatients.
Stuart GW; Malone V; Currie J; Klimidis S; Minas IH
Schizophr Res; 1995 Aug; 16(3):175-88. PubMed ID: 7488563
[TBL] [Abstract][Full Text] [Related]
7. Exploration of dimensions of psychopathology in neuroleptic-naïve patients with recent-onset schizophrenia/schizophreniform disorder.
John JP; Khanna S; Thennarasu K; Reddy S
Psychiatry Res; 2003 Nov; 121(1):11-20. PubMed ID: 14572620
[TBL] [Abstract][Full Text] [Related]
8. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
9. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms.
Keefe RS; Harvey PD; Lenzenweger MF; Davidson M; Apter SH; Schmeidler J; Mohs RC; Davis KL
Psychiatry Res; 1992 Nov; 44(2):153-65. PubMed ID: 1480680
[TBL] [Abstract][Full Text] [Related]
10. Symptom structure in schizophrenia: two-, three- or four-factor models?
Dollfus S; Everitt B
Psychopathology; 1998; 31(3):120-30. PubMed ID: 9636941
[TBL] [Abstract][Full Text] [Related]
11. Positive and negative symptoms in the psychoses. Re-analysis of published SAPS and SANS global ratings.
Klimidis S; Stuart GW; Minas IH; Copolov DL; Singh BS
Schizophr Res; 1993 Mar; 9(1):11-8. PubMed ID: 8461266
[TBL] [Abstract][Full Text] [Related]
12. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Abuzzahab FS; Zimmerman RL
J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
[TBL] [Abstract][Full Text] [Related]
13. Latent trait modelling of symptoms of schizophrenia.
Bell RC; Low LH; Jackson HJ; Dudgeon PL; Copolov DL; Singh BS
Psychol Med; 1994 May; 24(2):335-45. PubMed ID: 8084929
[TBL] [Abstract][Full Text] [Related]
14. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of discrepancy between self-ratings and examiner ratings for negative symptoms.
Selten JP; Wiersma D; van den Bosch RJ
Compr Psychiatry; 2000; 41(3):191-6. PubMed ID: 10834628
[TBL] [Abstract][Full Text] [Related]
16. Choosing negative symptom instruments: issues of representation and redundancy.
Welham J; Stedman T; Clair A
Psychiatry Res; 1999 Jul; 87(1):47-56. PubMed ID: 10512154
[TBL] [Abstract][Full Text] [Related]
17. Stability of positive and negative symptoms in schizophrenia.
Malla AK; Norman RM; Williamson P
Can J Psychiatry; 1993 Nov; 38(9):617-21. PubMed ID: 8306235
[TBL] [Abstract][Full Text] [Related]
18. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Gomez JC; Crawford AM
J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
[TBL] [Abstract][Full Text] [Related]
19. Variability in BPRS definitions of positive and negative symptoms.
Nicholson IR; Chapman JE; Neufeld RW
Schizophr Res; 1995 Oct; 17(2):177-85. PubMed ID: 8562492
[TBL] [Abstract][Full Text] [Related]
20. Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy.
Czobor P; Bitter I; Volavka J
Psychiatry Res; 1991 Feb; 36(2):129-39. PubMed ID: 2017528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
